Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study

Trial Profile

Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Romidepsin (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Vincristine
  • Indications Anaplastic large cell lymphoma; Peripheral T-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Dec 2018 Results (n=21, enrolled into phase Ib part of this study between Sep 2014 to Jul 2017) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 31 Aug 2018 Biomarkers information updated
    • 17 Jun 2018 Results of phase I part of the study (n=21, from September 2014 to July 2017) presented at the 23rd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top